HANGZHOU, China, Sept. 5, 2025 /PRNewswire/ -- Huadong Medicine Co., Ltd. (hereinafter referred to as "Huadong Medicine") today announced positive preliminary results from a Phase I study of HDM2005, an independently developed Class 1 innovative antibody–drug conjugate (ADC) targeting...
Hence then, the article about huadong medicine announces positive preliminary results from a phase study of hdm2005 a ror1 targeting adc was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Huadong Medicine Announces Positive Preliminary Results from a Phase Ⅰ study of HDM2005, a ROR1-Targeting ADC )
Also on site :
- Lauren Chapin, the Youngest Kid on ‘Father Knows Best,’ Dies at 80
- Wynn Resorts faces second lawsuit after data breach incident involving employees
- Angel Reese Stuns With Daring Pregame Outfit